Accelerate Diagnostics (AXDX) 10-K 7 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 25, 2014	Jun. 30, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'Accelerate Diagnostics, Inc.	'	'
Entity Central Index Key	'0000727207	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$107,800,000
Entity Common Stock, Shares Outstanding	'	41,904,521	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$30,028,961	$12,068,747
Investments	11,959,384	'
Trade accounts receivable	24,400	763,899
Prepaid expenses and other	130,190	16,379
Total current assets	42,142,935	12,849,025
Property and equipment, net	1,046,774	147,811
Intellectual property, net	240,668	319,280
Total Assets	43,430,377	13,316,116
Current liabilities:	'	'
Accounts payable	540,435	299,650
Accrued compensation and other liabilities	514,607	870,384
Deferred revenue and income	81,888	78,034
Total current liabilities	1,136,930	1,248,068
Long-term deferred income	776,667	'
Total liabilities	1,913,597	1,248,068
Stockholders' equity:	'	'
Common stock, $0.001 par value; 55,000,000 common shares authorized (as of December 31, 2013) and 45,000,000 shares (as of December 31, 2012) ; 41,649,521 (as of December 31, 2013) and 25,331,939 (as of December 31, 2012) shares issued and outstanding	$41,648	$25,332
Preferred stock, $0.001 par value; 5,000,000 shares authorized and none outstanding (as of December 31, 2013 and December 31, 2012)	$0.00	$0.00
Contributed capital	75,936,969	31,244,462
Accumulated deficit	-34,483,567	-19,201,746
Accumulated other comprehensive income	21,730	'
Total stockholders' equity	41,516,780	12,068,048
Total liabilities and stockholders' equity	$43,430,377	$13,316,116

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	55,000,000	45,000,000
Common Stock, shares issued	41,649,521	25,331,939
Common Stock, shares outstanding	41,649,521	25,331,939
Preferred stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares outstanding	'	'

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Loss (USD $)	5 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Revenues:	'	'	'	'	'
Technical development fees	'	$140,000	'	$140,000	$842,408
OptiChem revenue	17,712	62,008	48,285	45,910	34,279
License fees	'	'	'	50,000	'
Qualified discovery therapeutic grant	'	'	'	'	244,479
Total revenues	17,712	202,008	48,285	235,910	1,121,166
Costs and expenses:	'	'	'	'	'
Research and development	1,777,244	163,340	10,673,016	431,906	454,997
Sales, general and administrative	1,266,459	561,699	4,312,281	2,953,624	819,699
Amortization	38,023	64,087	76,903	203,460	253,499
Depreciation	4,644	515	285,592	2,097	2,396
Impairment of intangibles	333,487	'	11,352	1,996,583	'
Total costs and expenses	3,419,857	789,641	15,359,144	5,587,670	1,530,591
Loss from operations	-3,402,145	-587,633	-15,310,859	-5,351,760	-409,425
Other expense	'	'	-4,448	'	'
Interest and dividend income	1,921	4,047	33,486	16,297	16,092
Unrealized holding gain (loss) on investments	'	-4,368	'	23,987	14,572
Unrealized holding gain on asset sale	'	1,000	'	1,000	'
Total other income	1,921	679	29,038	41,284	30,664
Net loss	-3,400,224	-586,954	-15,281,821	-5,310,476	-378,761
Net loss per share:	'	'	'	'	'
Basic and diluted net loss per share	($0.13)	($0.05)	($0.41)	($0.43)	($0.04)
Weighted average shares outstanding	25,289,834	11,103,367	37,503,391	12,430,060	10,791,597
Other comprehensive loss:	'	'	'	'	'
Net loss	-3,400,224	-586,954	-15,281,821	-5,310,476	-378,761
Net unrealized gain/(loss) on available-for-sale investments	'	'	21,730	'	'
Comprehensive loss	($3,400,224)	($586,954)	($15,260,091)	($5,310,476)	($378,761)

Statement_of_Stockholders_Equi

Statement of Stockholders' Equity (USD $)	Common Stock	Contributed Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	For Employee Benefit	Total
Beginning Balance, Amount at Jul. 31, 2010	$14,138,820	$1,156,843	$0	($10,112,285)	($273,600)	$4,909,778
Beginning Balance, Shares at Jul. 31, 2010	10,757,317	'	'	'	'	10,757,317
Net Loss	'	'	'	-378,761	'	-378,761
Issuance of Common Stock and Warrants, Shares	'	'	'	'	'	'
Issuance of Common Stock and Warrants, Amount	'	'	'	'	'	'
Exercise of Options and Warrants, Shares	346,050	'	'	'	'	346,050
Exercise of Options and Warrants, Amount	194,438	'	'	'	'	194,438
Transfer of Rabbi Trust, Amount	'	'	'	'	'	'
Establish par value stock for DE Corp, Amount	'	'	'	'	'	'
Equity Based Compensation	'	90,021	'	'	'	90,021
Unrealized gain on available for sale securities	'	'	'	'	'	'
Ending Balance, Amount at Jul. 31, 2011	14,333,258	1,246,864	0	-10,491,046	-273,600	4,815,476
Ending Balance, Shares at Jul. 31, 2011	11,103,367	'	'	'	'	11,103,367
Net Loss	'	'	'	-5,310,476	'	-5,310,476
Issuance of Common Stock and Warrants, Shares	14,000,000	'	'	'	'	14,000,000
Issuance of Common Stock and Warrants, Amount	8,523,982	5,896,018	'	'	'	14,420,000
Exercise of Options and Warrants, Shares	128,572	'	'	'	'	128,572
Exercise of Options and Warrants, Amount	128,569	'	'	'	'	128,569
Transfer of Rabbi Trust, Amount	'	'	'	'	'	'
Establish par value stock for DE Corp, Amount	'	'	'	'	'	'
Equity Based Compensation	'	781,998	'	'	'	781,998
Unrealized gain on available for sale securities	'	'	'	'	'	'
Ending Balance, Amount at Jul. 31, 2012	22,985,809	7,924,880	0	-15,801,522	-273,600	14,835,567
Ending Balance, Shares at Jul. 31, 2012	25,231,939	'	'	'	'	25,231,939
Net Loss	'	'	'	-3,400,224	'	-3,400,224
Issuance of Common Stock and Warrants, Shares	'	'	'	'	'	'
Issuance of Common Stock and Warrants, Amount	'	'	'	'	'	'
Exercise of Options and Warrants, Shares	100,000	'	'	'	'	100,000
Exercise of Options and Warrants, Amount	100	99,900	'	'	'	100,000
Transfer of Rabbi Trust, Amount	'	-273,600	'	'	273,600	'
Establish par value stock for DE Corp, Amount	-22,960,577	22,960,577	'	'	'	'
Equity Based Compensation	'	532,705	'	'	'	532,705
Unrealized gain on available for sale securities	'	'	'	'	'	'
Ending Balance, Amount at Dec. 31, 2012	25,332	31,244,462	0	-19,201,746	0	12,068,048
Ending Balance, Shares at Dec. 31, 2012	25,331,939	'	'	'	'	25,331,939
Net Loss	'	'	'	-15,281,821	'	-15,281,821
Issuance of Common Stock and Warrants, Shares	2,487,562	'	'	'	'	2,487,562
Issuance of Common Stock and Warrants, Amount	2,488	19,908,727	'	'	'	19,911,215
Exercise of Options and Warrants, Shares	13,830,020	'	'	'	'	13,830,020
Exercise of Options and Warrants, Amount	13,828	20,955,302	'	'	'	20,969,130
Transfer of Rabbi Trust, Amount	'	'	'	'	'	'
Establish par value stock for DE Corp, Amount	'	'	'	'	'	'
Equity Based Compensation	'	3,828,478	'	'	'	3,828,478
Unrealized gain on available for sale securities	'	'	21,730	'	'	21,730
Ending Balance, Amount at Dec. 31, 2013	$41,648	$75,936,969	$21,730	($34,483,567)	$0	$41,516,780
Ending Balance, Shares at Dec. 31, 2013	41,649,521	'	'	'	'	41,649,521

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	5 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Cash flows from operating activities:	'	'	'	'	'
Net loss	($3,400,224)	($586,954)	($15,281,821)	($5,310,476)	($378,761)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'	'
Depreciation	4,644	515	285,592	2,097	2,396
Amortization of intangible assets	38,023	64,087	76,903	203,460	253,499
Amortization of investment discount	'	'	75,962	'	'
Stock-based compensation	532,705	272,529	3,828,478	781,998	90,021
Other expense, impairment loss	333,487	'	11,352	1,996,583	'
Unrealized gain on investments	'	'	'	-23,987	-14,572
Realized gain on sale of investments, interest and dividends reinvested	'	'	'	-7,944	-6,413
(Increase) decrease in assets:	'	'	'	'	'
Accounts receivable	-12,952	2,273	739,499	590,621	411,477
Inventory	10,263	'	'	20,015	2,342
Prepaid expense and other	1,549	-8,208	-113,811	2,649	-1,182
Increase (decrease) in liabilities:	'	'	'	'	'
Accounts payable	236,621	39,895	204,151	28,068	2,826
Accrued liabilities	127,042	7,391	-355,777	718,760	1,291
Deferred revenue and income	-7,311	95,479	780,521	75,548	-10,428
Deferred compensation	'	-72,569	'	106,936	95,985
Net cash (used in)/provided by operating activities	-2,136,153	-185,562	-9,748,951	-815,672	448,481
Cash flows from investing activities:	'	'	'	'	'
Purchases of equipment and capitalized patents	-158,348	-19,057	-1,157,564	-95,505	-75,336
Contribution to deferred compensation trust	'	16,319	'	-150,000	-75,000
Purchase of available-for-sale securities	'	'	-12,013,616	'	'
Net cash used in investing activities	-158,348	-2,738	-13,171,180	-245,505	-150,336
Cash flows from financing activities:	'	'	'	'	'
Exercise of warrants and options	100,000	'	20,969,130	128,569	194,438
Issuance of common stock and warrants	'	'	19,911,215	14,420,000	'
Net cash provided by financing activities	100,000	'	40,880,345	14,548,569	194,438
Increase (decrease) in cash and cash equivalents	-2,194,501	-188,300	17,960,214	13,487,392	492,583
Cash and cash equivalents, beginning of period	14,263,248	775,856	12,068,747	775,856	283,273
Cash and cash equivalents, end of period	$12,068,747	$587,556	$30,028,961	$14,263,248	$775,856

Organization_and_Nature_of_Bus

Organization and Nature of Business; Basis of Presentation	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization and Nature of Business; Basis of Presentation	'
	NOTE 1.  ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION
	Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) is a Delaware corporation focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The Company’s BACcelTM platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	NOTE 2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Recently Issued Accounting Pronouncements
	There have been no new accounting pronouncements issued but not yet adopted that are expected to materially affect the Company’s financial condition or results of operations.
	Use of Estimates
	The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.
	The Company periodically maintains cash balances at a commercial bank in excess of the Federal Deposit Insurance Corporation insurance limit of $250,000. At December 31, 2013 and December 31, 2012, the Company’s uninsured cash balance was approximately $30,105,171 and $12,004,575, respectively.
	The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At December 31, 2013 100% of the outstanding receivable balance was with Denver Health and the Department of Defense related to the Defense Medical Research and Development Program. See Note 7, License Agreements and Grants for more information.
	Estimated Fair Value of Financial Instruments
	The carrying amount of cash and cash equivalents, and other long-term liabilities approximates fair value at that respective period’s balance sheet date.
	The carrying value of all other financial instruments potentially subject to valuation risk, principally consisting of accounts receivable and accounts payable, also approximates fair value.
	The following methods and assumptions were used to estimate the fair value of financial instruments:
	Cash and Cash Equivalents – Generally, cash and cash equivalents consist of cash on deposit with banks, money market instruments, U.S. Treasury securities, and overnight repurchase agreements. The carrying amount approximates fair value.
	Investments – investments held are classified as available for sale securities and are included at amounts approximating the fair value of the underlying instruments.
	Cash and Cash Equivalents
	All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
	Investments
	The Company invests excess funds in various short-term and long-term investments. Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders’ equity. These available-for-sale investments are primarily held in the custody of a major financial institution. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.
	Property and Equipment
	Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from three to seven years. See Note 5, Property and Equipment below.
	Intellectual Property
	Intellectual property is amortized over the period the asset is expected to contribute directly or indirectly to the Company's future cash flows. The Company evaluates the remaining useful life of each intellectual property that is being amortized each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. Included in intellectual property are patents and technology. Intellectual properties are currently being amortized over their estimated useful lives of generally 20 years. See Note 6, Intellectual Property below.
	Long-lived Assets
	Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset. See Note 6, Intellectual Property below.
	Inventory
	The Company produces inventory prior to US FDA or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance or other non-US regulatory body equivalent. Accordingly, the Company does not capitalized pre-launch inventory prior to the receipt of 510(k) clearance, unless there are alternative uses of the inventory, regulatory approval has been achieved in other jurisdictions, or the regulatory review process has progressed to a point that the Company has objective and persuasive evidence that regulatory approval is probable.
	Revenue Recognition
	We recognize revenue in accordance with ASC 605, “Revenue Recognition,” when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.
	Technical development fee revenue was recorded in the period in which it was earned.
	OptiChem revenue is recognized when the Company ships the product to customers or upon the receipt of royalty payments from our licenses.
	Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.
	The Company recognizes income from royalty and licensing fee agreements bsed upon information and reports received from licensees and in accordance with the terms of the agreements underlying such arrangements.
	Deferred revenue represents amounts received but not yet earned under existing agreements.
	Accounts Receivable Allowances
	Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis.
	Income Taxes
	Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment. We provide a valuation allowance for deferred tax assets when it is more likely than not that the related benefits will not be realized.
	The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company’s income tax liabilities. Interest and penalties, if any, would be recorded to general and administrative expenses.
	Earnings Per Share
	The Company follows ASC 260, Earnings Per Share, which requires companies to present basic earnings per share and diluted earnings per share. Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.
	The Company’s net loss for the periods presented caused the inclusion of certain outstanding warrants and options to purchase our Common Stock to be antidilutive. For the period ended December 31, 2013 and the fiscal year ended December 31, 2012, there were Common Stock options and warrants exercisable for 5,731,246 (571,160 warrants and 5,160,086 options) and 18,431,930 (14,071,430 warrants and 4,360,500 options) shares of Common Stock, respectively, which were not included in diluted loss per share as the effect was antidilutive.
	Equity Based Compensation
	The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period. The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The Company’s expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award. The estimated expected option life is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. The Company has not paid dividends in the past and does not have any plans to pay any dividends in the future. See Note 11, Employee Stock Based Compensation for further information.
	Comprehensive Income (loss)
	The Company follows ASC 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Fair Value of Financial Instruments	'
	NOTE 3.   FAIR VALUE OF FINANCIAL INSTRUMENTS
	The carrying amounts of financial instruments such as cash equivalents, restricted cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments. The Company may invest its excess cash into financial instruments that are readily convertible into cash, such as marketable securities, money market funds and certificates of deposit with original maturities of three months or less at the date of purchase. The Company considers all highly liquid investments with maturities of three months or less from the date of purchase to be cash equivalents. The Company has established guidelines to maintain safety and liquidity for our financial instruments, and the cost of securities sold is based on the specific identification method.
	ASC Topic 820, Fair Value Measurements and Disclosures has redefined fair value and required the Company to establish a framework for measuring fair value and expand disclosures about fair value measurements. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:
		•		Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
		•		Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
		•		Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).
	The following tables represent the financial instruments measured at fair value on a recurring basis on the financial statements of the Company subject to ASC Topic 820, Fair Value Measurements and Disclosure, and the valuation approach applied to each class of financial instruments at December 31, 2013 and December 31, 2012:
			31-Dec-13
				Quoted prices in Active Markets for Identical Assets (Level 1)
						Significant Other Observable Imputs (Level 2)
								Significant Unobservable Inputs
								(Level 3)
										Total
	Assets:
	Money market funds (cash equivalents)		$	27,095,852	$	—	$	—	$	27,095,852
	Corporate notes and bonds			—		11,459,357		—		11,459,357
	Asset-backed securities			—		500,027		—		500,027
	Total assets measured at fair value		$	27,095,852	$	11,959,384	$	—	$	39,055,236
			31-Dec-12
				Quoted Prices in Active Markets for Identical Assets (Level 1)
						Significant Other Observable Inputs (Level 2)
								Significant Unobservable Inputs
								(Level 3)
										Total
	Assets:
	Repurchase agreement (cash equivalents)		$	12,004,575	$	—	$	—	$	12,004,575
	Total assets measured at fair value		$	12,004,575	$	—	$	—	$	12,004,575
	Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs. There were no significant transfers between levels during the year ended December 31, 2013.

Investments

Investments	12 Months Ended
	Dec. 31, 2013
Investments, All Other Investments [Abstract]	'
Investments	'
	NOTE 4.  INVESTMENTS
	The following tables summarize the Company’s available-for-sale investments at December 31, 2013:
					Gross Unrealized Gains		Gross Unrealized Losses
			Amortized Cost
										Fair Value
	Asset-backed securities	$	500,113	$	—	$	(86	)	$	500,027
	Corporate notes and bonds		11,437,541		22,825		(1,009	)		11,459,357
	Total	$	11,937,654	$	22,825	$	(1,095	)	$	11,959,384
	The following table summarizes the maturities of the Company’s available-for-sale securities at December 31, 2013:
		Amortized		Fair Value
		Cost
	Due in less than 1 year	$	4,999,251	$	5,001,969
	Due in 1-2 years		6,938,403		6,957,415
	Total	$	11,937,654	$	11,959,384

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	NOTE 5.  PROPERTY AND EQUIPMENT
	Property and equipment are recorded at cost and consisted of the following as of years ending December 31, 2013 and 2012.
	PROPERTY AND EQUIPMENT
			12/31/13			12/31/12
	Computer equipment	$	566,471		$	89,109
	Laboratory and scientific equipment		791,295			323,151
	Furniture and fixtures		36,988			36,988
	Leasehold improvements		278,791			39,741
	Total property and equipment	$	1,673,545		$	488,989
	Accumulated depreciation		(626,771	)		(341,178	)
	Net property and equipment	$	1,046,774		$	147,811
	Depreciation expense for the for the twelve months ended December 31, 2013, five months ended December 31, 2012 and 2011, and twelve months ended July 31, 2012 and 2011 was $285,592, $4,644, $515, $2,097 and $2,396, respectively.

Intellectual_Property

Intellectual Property	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intellectual Property	'
	NOTE 6.  INTELLECTUAL PROPERTY
	Intellectual property consisted of the following at the dates indicated:
	INTELLECTUAL PROPERTY
				12/31/13				12/31/12
	OptiChem Technologies		$	192,954			$	192,954
	Patents			210,125				211,833
	Subtotal		$	403,079			$	404,787
	Accumulated amortization			(162,411	)			(85,507	)
	Net intellectual property		$	240,668			$	319,280
	Future amortization expense for the intangible assets is estimated as follows:
	Years Ending December 31,
		2014			$	63,313
		2015				8,082
		2016				8,082
		2017				8,082
		Thereafter				153,109
		Total future amortization			$	240,668
	Intellectual properties are recorded at cost and are being amortized on a straight-line basis over their estimated useful lives of 20 years or the patent application life specific to each capitalized patent. Amortization expense for the twelve months ended December 31, 2013, five months ended December 31, 2012 and 2011, and twelve months ended July 31, 2012 and 2011 was $76,903, $38,023, $64,087, $203,460 and $253,499, respectively. The Company routinely evaluates the recoverability of its long-lived assets based upon estimated future cash flows from and estimated fair value of such long-lived assets. If in management’s judgment, the anticipated undiscounted cash flows or estimated fair value are insufficient to recover the carrying amount of the long-lived asset, the Company will determine the amount of the impairment and the value of the asset will be written down. Management determined that certain capitalized intellectual property amounts carried on our balance sheet are no longer recoverable or abandoned its plan to pursue marketability and accordingly reduced the amortized book values and recognized the loss in its reported loss from operations for the twelve months ended December 31, 2013, five months ended December 31, 2012 and 2011, and twelve months ended July 31, 2012 and 2011 amounting to $11,352, $333,487, $0, $1,996,583 and $0, respectively.

License_Agreements_and_Grants

License Agreements and Grants	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
License Agreements and Grants	'
	NOTE 7.  LICENSE AGREEMENTS AND GRANTS
	The Company signed a licensing agreement for microarraying slides using OptiChem coatings with Schott Jenaer Glas GmbH (“SCHOTT”) on November 4, 2004. Since this time, SCHOTT and the Company have extended this license. On August 15, 2011, Schott Technical Glass Solutions GmbH renewed and expanded its licenses for OptiChem microarray slide products, designated as Schott Nexterion Slide H and Slide HS. The terms remain substantially the same as in previous agreements, with the expansion to include microarray slide products intended for use in medical diagnostic devices. Previous agreements excluded medical applications. This expansion makes SCHOTT the second company that intends to use OptiChem coatings on medical devices.
	The new agreement extends the non-exclusive license through November 24, 2014. SCHOTT paid the Company $150,000 comprised of a one-time license fee ($50,000) and non-refundable prepaid royalties ($100,000). Royalties consist of 5% of SCHOTT’s net product sales. The prepaid royalty has been recognized as deferred revenue, and is recognized as SCHOTT’s net product sales are reported to the Company. For medical applications, SCHOTT agrees to refer individual customers directly to the Company for licensing if annual purchases by a customer exceed 20,000 units.
	On October 5, 2007, the Company entered into an exclusive seven-year license with NanoString Technologies, Inc. (“NanoString”). The license grants NanoString the right to apply OptiChem coatings to NanoString’s proprietary molecular detection products.
	On July 9, 2010 the Company entered into a non-exclusive license to Nanosphere, Inc. The license grants to Nanosphere the right to apply OptiChem coatings to Nanosphere’s proprietary analytical products. The products may also include FDA-regulated diagnostics devices. Pursuant to the license agreement, Nanosphere paid the Company a non-refundable first-year fee of $150,000 plus a $15,000 technology transfer fee. On each anniversary of the agreement date, the license calls for Nanosphere to pay to the Company the amounts of $350,000 in 2011; $600,000 in 2012, and $750,000 in 2013 in order to complete the payments for rights under the remaining patent life. The final installment of this arrangement for $750,000 was received in full on July 8, 2013. All of the amounts due from Nanosphere were recognized as OptiChem revenue during the fiscal year ended July 31, 2010.
	In May 2012, the Company and Denver Health were notified that the Defense Medical Research and Development Program (“DMRDP”) recommended $2 million of funding for a proposed 35-month project of which the Company estimates it will receive direct monies for internal research and development of $650,000. The joint proposal became the sole recipient under the Military Infectious Diseases Applied Research Award program for rapid detection of serious antibiotic-resistant infections.  The project will apply the Company’s BACcel rapid diagnostic system to wound infections and other serious infections secondary to trauma. As of December 31, 2013 the Company has invoiced $158,287 ($142,591 for year ended December 31, 2013, and $15,696 for the year ended December 31, 2012) under this grant recorded as an offset to research and development expenses.
	On August 22, 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority will provide certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of $1,000,000 (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in four installments, upon the achievement of the following milestones:
		·	Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of 15 Qualified Jobs (as defined below).
		·	Milestone 2 – Creation of 30 Qualified Jobs (including Qualified Jobs under Milestone 1).
		·	Milestone 3 – Creation of 40 Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).
		·	Milestone 4 – Creation of 65 Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least $4,520,000.
	For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least $63,000 and offers health insurance benefits and pays at least 65% of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of December 31, 2013 the Company has collected $750,000 of the $1,000,000 in milestones. The full amount is recorded in deferred revenue (long term liabilities) until the economic development provisions of the grant have been satisfied in full, as there are ‘claw-back’ provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the ‘claw-back’ provisions expire, we will recognize the grant as other non-operating income.

Deferred_Revenue_and_Income

Deferred Revenue and Income	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Deferred Revenue and Income	'
	NOTE 8.  DEFERRED REVENUE AND INCOME
	Deferred revenue consists of amounts received for products or services not yet delivered or earned. Deferred income consists of amounts received for commitments not yet fulfilled. If we anticipate that the revenue or income will not be earned within the following fiscal year, the amount is reported as long-term deferred income. A summary of the balances as of December 31, 2013 and 2012 follow:
	Deferred Revenue and Income
			12/31/13		12/31/12
	Schott Royalties (see Note 7)	$	68,555	$	72,757
	NanoString (see Note 7)		—		5,276
	Fisher Agreement		13,333		—
	Total deferred revenue and income	$	81,888	$	78,034
	Arizona Commerce Authority Grant (see Note 7)	$	750,000		—
	Fisher Agreement		26,667		—
	Total Long-term deferred income	$	776,667	$	0
	Deferred revenue recognized was approximately $9,478, $7,311, $4,521, $24,452 and $10,428 during the year ended December 31, 2013, five-month period ended December 31, 2012 and 2011, and the fiscal years ended July 31, 2012 and 2011, respectively. Deferred revenue consists of prepaid royalty fees from Nanostring and SCHOTT. During the year ended July 31, 2012 an additional $100,000 was received from SCHOTT as prepaid royalties of which $4,202, $7,311, $0, $19,931 and $0 was recognized during the year ended December 31, 2013, five-month period ended December 31, 2012 and 2011, and the fiscal years ended July 31, 2012 and 2011, respectively and are reflected as OptiChem revenues.
	In the year ended December 31, 2013, $40,000 was received from Fisher Laboratory of which none has been recognized as income. We anticipate earning $13,333 of this amount in the next fiscal year and the remaining $26,667 in future years.
	Also in the year ended December 31, 2013, $750,000 in milestone payments from the Arizona Commerce Authority were received of which none has been recognized in income and we do not anticipate earning any of it in the next fiscal year. Further details of the Arizona Commerce Authority agreement are in Note 7, License Agreements and Grants.

Stock_Purchase

Stock Purchase	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Stock Purchase	'
	NOTE 9.  STOCK PURCHASE
	On April 20, 2012, we entered into a Securities Purchase Agreement with Abeja Ventures, LLC (“Abeja”), pursuant to which the Company agreed to sell and issue to Abeja at a purchase price of $1.03 per share for an aggregate purchase price of $14,420,000; (i) 14,000,000 shares of the Company’s Common Stock; (ii) a warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $1.03 per share (the “$1.03 Warrant”); and (iii) another warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $2.00 per share (the “$2.00 Warrant”), with each warrant exercisable prior to the fifth anniversary of the closing of the transactions contemplated by the Securities Purchase Agreement (collectively, the “Investment”). The purchase of Common Stock and warrants pursuant to the Investment, which was consummated on June 26, 2012, qualified for equity treatment under Generally Accepted Accounting Principles. The respective values of the warrants and Common Stock were calculated using their relative fair values and both are classified under Contributed Capital. The value therefore recorded for the warrants is $5,896,018 and for the Common Stock is $8,523,982.
	As noted above, the warrants sold by the Company include (i) a warrant to purchase 7,000,000 shares of the Company’s common stock at an exercise price of $1.03 per share, and (ii) a warrant to purchase an additional 7,000,000 shares of the Company’s common stock at an exercise price of $2.00 per share. Both warrants were exercisable until June 26, 2017, which was the fifth anniversary of the date on which the warrants were issued. Other significant terms and conditions of the warrants are as follows:
		·	the warrants provide for partial exercises, but they do not provide for a “cashless” exercise feature (i.e., they may only be exercised for cash);
		·	the warrants do not contain anti-dilution provisions that would trigger exercise price or other adjustments as a result of subsequent issuances of the Company’s equity securities, but they do contain customary provisions for equitable adjustments in connection with stock dividends, stock splits or reclassifications of the Company’s common stock;
		·	following certain types of fundamental transactions involving the Company (e.g., a transaction resulting in a change in control of the Company), the holder of the warrants would continue to be entitled to exercise the warrants in exchange for the equity securities or alternate consideration receivable by a holder of the Company’s common stock as a result of the fundamental transaction; and
		·	the holder of the warrants is entitled to certain demand and piggy-back registration rights, including for shelf registrations, with respect to the shares of common stock issuable upon its exercise of the warrants.
	On March 6, 2013, Abeja exercised in full its warrant to purchase 7,000,000 shares of the Company’s Common Stock at an exercise price of $1.03 per share. On the same date, Abeja also exercised the 92% of its warrant to purchase an additional 7,000,000 shares of the Company’s Common Stock at an exercise price of $2.00 per share (Abeja exercised such warrant for 6,428,840 shares, leaving 571,160 shares unexercised). The Company received aggregate funds of $20,067,680 in connection with such exercises. Shares issued by the Company in connection with the warrant exercises were issued directly to the members of Abeja on a pro rata basis in accordance with their membership interests and written exercise instructions provided to the Company by Abeja. Immediately after giving effect to the warrant exercises, Abeja also distributed in kind to its members (on a pro rata basis in accordance with their membership interests) the remaining shares of Common Stock held by that entity.

Rights_Offering

Rights Offering	12 Months Ended
	Dec. 31, 2013
Equity Method Investments and Joint Ventures [Abstract]	'
Rights Offering	'
	NOTE 10.  RIGHTS OFFERING
	On July 12, 2013, the Company publicly announced the final terms of a rights offering. Rights offering materials were subsequently distributed to the Company’s stockholders on July 18, 2013, at which time the rights offering period commenced. Pursuant to the terms of the rights offering, the Company distributed, at no charge to the holders of its Common Stock as of 5:00 p.m., New York City time, on July 8, 2013, which was established as the record date for the rights offering, 0.064038 non-transferable subscription rights for each share of Common Stock owned on the record date. Each whole subscription right allowed the holder to subscribe to purchase one share of Common Stock at a subscription price of $8.04 per share. In addition, any holder of subscription rights exercising his, her or its basic subscription privilege in full was eligible to subscribe to purchase additional shares of Common Stock at the same subscription price per share, subject to the conditions and limitations described further in the prospectus.
	In connection with the rights offering, the Company received a standby commitment from Abeja to purchase, at $8.04 per share, any and all shares of Common Stock that were not subscribed for by stockholders in connection with the rights offering.
	The rights offering period expired at 5:00 p.m., New York City time, on August 7, 2013, and the transactions contemplated by the rights offering and the Standby Purchase Agreement described above (including the Company’s issuance of an aggregate of 2,487,562 shares of its Common Stock to the rights offering participants and standby purchaser) were completed on August 8, 2013. The Company received gross proceeds of $20,000,000 before costs associated with the transactions, which totaled $88,785.

Employee_Stock_Based_Compensat

Employee Stock Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Employee Stock Based Compensation	'
	NOTE 11.  EMPLOYEE STOCK BASED COMPENSATION
	The Company has three stock-based compensation plans, which are discussed below:
	Qualified Stock Option Plan
	The Qualified Stock Option Plan (the “Qualified Plan”) was a stockholder-approved plan that provided for stock option grants to employees, including executive officers. The exercise price of each option, which has a maximum ten-year life, was established by the Company's Compensation Committee on the date of grant.
	As of December 31, 2013, there were 322,500 options exercised under the Qualified Plan and 235,000 that remain outstanding. The Qualified Plan has been dissolved, so no further options are available for grant.
	Non-Qualified Stock Option Plan
	The Non-Qualified Stock Option Plan (the “Non-Qualified Plan”) was a stockholder-approved plan that provided for stock option grants to independent contractors, technical advisors and directors of the Company. The exercise price of each option, which has a maximum ten-year life, was established by the Company's Compensation Committee on the date of grant.
	As of December 31, 2013, there were 245,000 options exercised under the Non-Qualified Plan and 10,000 that remain outstanding. The Non-Qualified Plan has been dissolved, so no further options are available for grant.
	2004 Omnibus Stock Option Plan and 2012 Omnibus Equity Incentive Plan
	On December 14, 2004 the Company’s stockholders approved the Omnibus Stock Option Plan and reserved 500,000 shares of its authorized but unissued Common Stock for stock options to be granted to employees, independent contractors, technical advisors and directors of the Company. The authorized shares in this plan were increased by 5,000,000 shares to an aggregate amount of 5,500,000 upon stockholder approval during the fiscal year ended July 31, 2012.
	On December 12, 2012 the Company’s stockholders approved the Company’s 2012 Omnibus Equity Incentive Plan to replace the 2004 Omnibus Stock Option Plan. In connection with the approval of such plan, all shares formerly available for new awards under the 2004 Omnibus Stock Option Plan were transferred to the 2012 Omnibus Equity Incentive Plan.
	As of December 31, 2013, 268,000 options had been exercised pursuant to the 2012 Omnibus Equity Incentive Plan, 4,915,086 that remain outstanding, leaving 316,914 available for grant.
	Accounting for Employee Based Option Plans
	As discussed in Note 2, Summary of Significant Accounting Policies, the Company accounts for all option grants using the Black-Scholes option pricing model in accordance with ASC 718 for options granted or extended.
	On December 31, 2013, there were Common Stock options outstanding at exercise prices ranging from $1.04 to $13.30 per share with expiration dates between March 15, 2015 and November 5, 2023. At December 31, 2013 and December 31, 2012, stock options and warrants exercisable into 5,731,246 and 18,431,930 shares of Common Stock, respectively, were not included in the computation of diluted earnings per share because their effect was antidilutive.
	For the years ending ended December 31, 2013 and 2012, the Company accounted for the compensation cost related to awards of stock options and other equity-based instruments to its employees, directors and consultants based on the fair value of the instrument on the grant date, and recognized this cost using the accelerated attribution method over the requisite service period. During the year ended December 31, 2013, the Company issued options to purchase a total of 1,308,086 common shares at an average exercise price of $7.56 per share.
	The fair value of options granted under the stock option agreements and stock-based compensation plans discussed above is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants in the year ended December 31, 2013: no expected dividend yield; risk free interest rate of 0.793% to 2.193%; expected life of 5.27 to 6.50 years; and expected volatility of 91% to 100%. The weighted average remaining contractual life of options outstanding at December 31, 2013 was 8.53 years. Weighted average expected forfeiture rate used was 14%.
	As of December 31, 2013 and 2012, unrecognized share-based compensation cost related to unvested stock options was $6,339,510 and $3,421,901, respectively. For the year ended December 31, 2013, the five-month periods ended December 31, 2012 and 2011, and the fiscal years ended July 31, 2012 and 2011, the Company recognized $3,828,478, $532,705, $272,529, $781,998 and $90,021, respectively in stock-based compensation costs related to the issuance of stock options to employees.
	The following table summarizes information on stock option activity for the Omnibus Plan, the Qualified Plan and the Non-Qualified Plan.
					Weighted
					Average
		Number of	Exercise Price		Exercise Price
		Shares	Per Share		Per Share
	Options Outstanding July 31, 2012	3,180,000	$0.73-4.50	$	1.56
	Granted	1,433,000	$2.98-3.95	$	3.65
	Cancelled	250,000	$2.25-4.50	$	3.34
	Exercised	—	—		—
	Expired	2,500	$2.36-3.20	$	3.02
	Options Outstanding December 31, 2012	4,360,500	$0.73-3.95	$	2.14
	Granted	1,308,086	$3.45-13.30	$	7.56
	Cancelled	58,000	$2.69-9.83	$	6.47
	Exercised	328,000	$1.04-3.69	$	2.54
	Expired	122,500	$0.73-3.20	$	1.78
	Options Outstanding December 31, 2013	5,160,086	$1.04-13.30	$	3.45
	As of December 31, 2013 and December 31, 2012, 1,021,056 and 1,360,500 options outstanding were currently exercisable and carried weighted average exercise prices of $2.29 and $1.92 respectively. The following table summarizes information about stock options outstanding and exercisable at December 31, 2013:
			Outstanding				Exercisable
	Range of Exercise Price	Number of Shares	Weighted Average Remaining Contractual Life		Weighted Average Exercise Price	Number of Shares	Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
	$0 to $3.50	2,605,000	8.17	$	1.31	775,000	7.73	$	1.4
	$3.51 to $7.00	2,053,691	8.69		4.45	244,120	7.05		5.01
	$7.01 to $10.50	394,500	9.66		9.71	—	—		—
	$10.51 to $13.50	106,895	9.85		13.3	1,936	9.85		13.3
	Total	5,160,086	8.53	$	3.45	1,021,056	7.57		2.29

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	NOTE 12.  INCOME TAXES
	The components of the income tax provision (benefit) are as follows:
				12/31/13			12/31/12		7/31/12		7/31/11
	Current		$	—		$	—	$	—	$	—
	Deferred			—			—		—		—
	Total		$	—		$	—	$	—	$	—
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred income taxes are as follows:
			12/31/13			12/31/12
	Deferred tax assets:
	Intangible assets, definite-lived	$	478,000		$	452,000
	Property & equipment		21,000			—
	Deferred revenue		26,000			30,000
	Charitable contribution		11,000			6,000
	Stock options		516,000			172,000
	Officer’s compensation		—			270,000
	General business credit		637,000			144,000
	Net operating loss carryforward		8,595,000			4,083,000
	Valuation allowance		(10,284,000	)		(5,156,000	)
	Deferred tax assets	$	—		$	1,000
	Deferred tax liabilities:
	Property & equipment	$	—		$	(1,000	)
	Total deferred tax liabilities	$	—		$	(1,000	)
	Total net deferred taxes	$	—		$	—
	As of December 31, 2013, the Company has generated regular tax net operating losses of approximately $28,000,000. Our ability to utilize our U.S. federal and state NOLs may be limited if we experience an ownership change as defined by U.S. Internal Revenue Code Section 382. When a company undergoes an ownership change, Section 382 limits the future use of NOLs generated before the change in ownership and certain subsequently recognized “built-in” losses and deductions, if any, existing as of the date of the ownership change. A company’s ability to utilize new NOLs arising after the ownership change is not affected. At this time, we have not performed an analysis under Section 382 to determine if an ownership change has occurred. The Company has estimated that due to Abeja Ventures, LLC’s investment in the company on June 26, 2012, the annual Section 382 limitation on utilization of net operating losses will be $420,000. The gross net operating losses available for future use are approximately $24,000,000. For federal purposes, net operating losses can be carried forward for up to 20 years. The Company’s net operating losses will begin to expire in 2023.
	Additionally, the Company has relocated its headquarters to Arizona and will begin filing tax returns in Arizona starting with the year ending December 31, 2013. The Colorado net operating loss carryovers may not be utilized and as a result are fully reserved. The deferred attributes have been adjusted to reflect the change to the Arizona state income tax rates.
	The valuation allowance is $10,284,000 as of December 31, 2013 compared to $5,156,000 as of December 31, 2012. The valuation allowance is based on management’s assessment that it is more likely than not that the Company will not have taxable income in the foreseeable future.
	The difference between the U.S. federal statutory income tax rate and the Company’s effective tax rate is as follows:
	Fiscal year ended,		12/31/13			12/31/12		7/31/12		7/31/11
	U.S. Federal statutory income tax rate		(34.00	)%		(34.00	)%	(34.00	)%	(34.00	)%
	State taxes, net of federal tax benefit		(3.80	)		(2.70	)	(3.00	)	(3.00	)
	Change in state rate		0			(0.90	)	—		—
	Non-deductible equity and other compensation		6.5			4.2		5.19		0.1
	Limitation on net operating losses due to S382		1			32.5		—		—
	Removal of Colorado net operating losses		0			10.8		—		—
	Prior period net operating loss correction		—			—		(1.70	)	—
	Credit for increased research activities		(3.20	)		—		—		—
	Change in valuation allowance		33.5			(9.90	)	33.51		36.9
			0	%		0	%	0	%	0	%

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments	'
	NOTE 13.  COMMITMENTS
	Employment Agreement and Consulting Agreement
	Effective December 1, 2007, we entered into an Employment Agreement with Mr. Geimer. The agreement provided for an annual base salary of $165,000 with annual deferred compensation of $75,000 and was to have expired on December 31, 2012. On June 26, 2012, Thomas V. Geimer resigned as the Company’s Chief Executive Officer, Chief Financial Officer and Secretary. In connection with his resignation, Mr. Geimer entered into an Amendment to Employment Agreement with the Company, as well as a new Consulting Agreement. Pursuant to the Amendment to Employment Agreement, Mr. Geimer and the Company agreed to stagger certain payments due to him such that $650,000 was paid to Mr. Geimer upon the closing of the Investment and $700,000 payable to him on July 1, 2013. Any payments due to Mr. Geimer under his Employment Agreement (as amended) but not timely paid by the Company bear interest at a rate of 18% per annum. In addition, the $75,000 deferred compensation payment for the Company’s fiscal year ending July 31, 2012 was contributed prior to the closing of the Investment. Pursuant to the Consulting Agreement, Mr. Geimer agreed to provide certain transition and other services to the Company. In exchange, during the remainder of 2012, the Company paid Mr. Geimer an amount equal to $24,000 per month. From January 1, 2013 through December 31, 2013, Mr. Geimer’s aggregate consulting fee was $96,000 ($8,000 per month). As of December 31, 2013, no additional amounts are due under this consulting agreement.
	Operating Lease
	As of December 31, 2012, the Company was a party to a lease for office and laboratory space located in Denver, Colorado that subsequently expired on February 1, 2013 (pursuant to an extension effective as of August 3, 2012). Total rent expense including common area charges was approximately $10,844, $39,867, $35,470, $73,965 and $68,330 during the year ended December 31, 2013, five-month period ended December 31, 2012 and 2011, and the fiscal years ended July 31, 2012 and 2011, respectively.
	On August 20, 2012, the Company entered into a Lease Agreement (“Lease”) with Pima County, a political subdivision of the State of Arizona (“Landlord”), pursuant to which the Company will lease approximately 15,096 square feet of office space located in Tucson, Arizona for a period of three years (the “Initial Term”), which may be extended by the Company for up to three additional one-year periods (each a “Renewal Term”). The Lease also provides that the Company has the option, with six months prior notice to Landlord, to lease either or both of two additional areas with an aggregate size of approximately 7,920 square feet.
	Pursuant to the Lease, the Company agreed to: (i) pay rent equal to $9.25 per usable square foot per year (approximately $139,600 per year or approximately $11,600 per month) during the Initial Term and $19.80 per usable square foot per year (approximately $298,900 per year or approximately $24,900 per month) during any Renewal Term; (ii) relocate its corporate offices to the Tucson area and begin operations within 30 days of the date that the tenant improvements are substantially completed (the “Commencement Date”); and (iii) within 18 months of the Commencement Date, employ at least 30 individuals with a median salary of at least $70,000, which median salary must be maintained throughout the term of the Lease. If the Company fails to satisfy the condition described in clause (iii) of the preceding sentence, the rental rate under the Lease will be increased by a percentage that is twice the percentage by which the Company’s annual payroll has fallen short of the specified goal (subject to a cap equal to $19.80 per usable square foot per year). The Lease also provides that Landlord will pay for tenant improvements (up to a cap of $1,400,000) as well as certain repairs, utilities and insurance.
	As of February 1, 2013, we relocated our headquarters into the above described leased space in Tucson, Arizona. Total rent expense including common area charges was approximately $167,864 during the year ended December 31, 2013 with no amounts in previous periods. Future minimum lease payments under this agreement are as follows:
			2014		2015		2016		2017		2018
	Operating Lease Obligations	$	141,664	$	141,664	$	1,164	$	—	$	—

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	NOTE 14.  SUBSEQUENT EVENTS
	In January 2014, we completed a 4,332 square foot expansion of our facility in Tucson, Arizona to accommodate growth. We anticipate adding an additional 7,553 square feet in 2014 for manufacturing and other operational needs.
	On January 8, 2014, we were notified by the Arizona Commerce Authority (“Authority”) that we meet the program requirements to receive a “Certificate of Qualification” and, therefore, are eligible for a partial refund of research and development investments. Our research and development tax credit for 2013 is $703,377 which makes us eligible to claim a partial refund of 75% or $527,495. By claiming this partial refund, we irrevocably forfeit the remaining 25% tax credit amount along with any additional tax credits that might become available if our qualifying expenses increase or income tax liability decreases. The “Certificate of Qualification” does not guarantee the receipt of tax incentives; nor does it obligate the Arizona Department of Revenue to issue the refund. Furthermore, if qualifying expenses decrease or income tax liability increases, the refund amount may be less than the $527,495. If the amount received for this tax credit is later determined to be incorrect or invalid, the excess may be treated as a tax deficiency.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	There have been no new accounting pronouncements issued but not yet adopted that are expected to materially affect the Company’s financial condition or results of operations.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.
	The Company periodically maintains cash balances at a commercial bank in excess of the Federal Deposit Insurance Corporation insurance limit of $250,000. At December 31, 2013 and December 31, 2012, the Company’s uninsured cash balance was approximately $30,105,171 and $12,004,575, respectively.
	The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. At December 31, 2013 100% of the outstanding receivable balance was with Denver Health and the Department of Defense related to the Defense Medical Research and Development Program. See Note 7, License Agreements and Grants for more information.
Estimated Fair Value of Financial Instruments	'
	Estimated Fair Value of Financial Instruments
	The carrying amount of cash and cash equivalents, and other long-term liabilities approximates fair value at that respective period’s balance sheet date.
	The carrying value of all other financial instruments potentially subject to valuation risk, principally consisting of accounts receivable and accounts payable, also approximates fair value.
	The following methods and assumptions were used to estimate the fair value of financial instruments:
	Cash and Cash Equivalents – Generally, cash and cash equivalents consist of cash on deposit with banks, money market instruments, U.S. Treasury securities, and overnight repurchase agreements. The carrying amount approximates fair value.
	Investments – investments held are classified as available for sale securities and are included at amounts approximating the fair value of the underlying instruments.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe however, that the market risk arising from holding these financial instruments is minimal.
Investments	'
	Investments
	The Company invests excess funds in various short-term and long-term investments. Investments consist of debt securities in U.S. government-sponsored entities, corporate debt securities and commercial paper. Management classifies its investments as available-for-sale investments and records these investments in the Balance Sheets at fair value. Unrealized gains or losses for available-for-sale securities are included in accumulated other comprehensive income or loss, a component of stockholders’ equity. These available-for-sale investments are primarily held in the custody of a major financial institution. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from three to seven years. See Note 5, Property and Equipment below.
Intellectual Property	'
	Intellectual Property
	Intellectual property is amortized over the period the asset is expected to contribute directly or indirectly to the Company's future cash flows. The Company evaluates the remaining useful life of each intellectual property that is being amortized each reporting period to determine whether events and circumstances warrant a revision to the remaining period of amortization. Included in intellectual property are patents and technology. Intellectual properties are currently being amortized over their estimated useful lives of generally 20 years. See Note 6, Intellectual Property below.
Long-lived Assets	'
	Long-lived Assets
	Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset. See Note 6, Intellectual Property below.
Inventory	'
	Inventory
	The Company produces inventory prior to US FDA or other regulatory agency approval. We do not believe probable future economic benefit can be asserted prior to the completion of 510(k) clearance or other non-US regulatory body equivalent. Accordingly, the Company does not capitalized pre-launch inventory prior to the receipt of 510(k) clearance, unless there are alternative uses of the inventory, regulatory approval has been achieved in other jurisdictions, or the regulatory review process has progressed to a point that the Company has objective and persuasive evidence that regulatory approval is probable.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue in accordance with ASC 605, “Revenue Recognition,” when persuasive evidence of an arrangement exists, the price is fixed or determinable, collection is reasonably assured and delivery of products has occurred or services have been rendered.
	Technical development fee revenue was recorded in the period in which it was earned.
	OptiChem revenue is recognized when the Company ships the product to customers or upon the receipt of royalty payments from our licenses.
	Additional considerations include whether the applicable fee arrangement contains future delivery or performance obligations that should be divided into separate accounting units, whether the arrangement requires the Company to retain risks consistent with a collaborative arrangement, and/or whether any of the fees are contingent on the achievement of future milestones.
	The Company recognizes income from royalty and licensing fee agreements bsed upon information and reports received from licensees and in accordance with the terms of the agreements underlying such arrangements.
	Deferred revenue represents amounts received but not yet earned under existing agreements.
Accounts Receivable Allowances	'
	Accounts Receivable Allowances
	Allowances on accounts receivable are recorded when circumstances indicate collection is doubtful for a particular accounts receivable. Receivables are written off if reasonable collection efforts prove unsuccessful. The Company provides for allowances on a specific account basis.
Income Taxes	'
	Income Taxes
	Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment. We provide a valuation allowance for deferred tax assets when it is more likely than not that the related benefits will not be realized.
	The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under GAAP, in order to recognize an uncertain tax benefit the taxpayer must be more likely than not of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more than 50% likely to be realized upon resolution of the benefit. The Company determined that no uncertain tax positions have been taken or are expected to be taken that could have a material effect on the Company’s income tax liabilities. Interest and penalties, if any, would be recorded to general and administrative expenses.
Earnings Per Share	'
	Earnings Per Share
	The Company follows ASC 260, Earnings Per Share, which requires companies to present basic earnings per share and diluted earnings per share. Basic earnings (loss) per share includes no dilution and is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period.
	The Company’s net loss for the periods presented caused the inclusion of certain outstanding warrants and options to purchase our Common Stock to be antidilutive. For the period ended December 31, 2013 and the fiscal year ended December 31, 2012, there were Common Stock options and warrants exercisable for 5,731,246 (571,160 warrants and 5,160,086 options) and 18,431,930 (14,071,430 warrants and 4,360,500 options) shares of Common Stock, respectively, which were not included in diluted loss per share as the effect was antidilutive).
Equity Based Compensation	'
	Equity Based Compensation
	The Company awards stock options and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity based awards is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period. The Company estimates the fair value of stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield. The Company’s expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award. The estimated expected option life is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. The Company has not paid dividends in the past and does not have any plans to pay any dividends in the future. See Note 11, Employee Stock Based Compensation for further information.
Comprehensive Income (loss)	'
	Comprehensive Income (loss)
	The Company follows ASC 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income (loss) and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company holds investments classified as available-for-sale securities and records the change in fair market value as a component of comprehensive income (loss).

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Fair Value Measurement	'
		31-Dec-13
			Quoted prices in Active Markets for Identical Assets (Level 1)
					Significant Other Observable Imputs (Level 2)
							Significant Unobservable Inputs
							(Level 3)
									Total
	Assets:
	Money market funds (cash equivalents)	$	27,095,852	$	—	$	—	$	27,095,852
	Corporate notes and bonds		—		11,459,357		—		11,459,357
	Asset-backed securities		—		500,027		—		500,027
	Total assets measured at fair value	$	27,095,852	$	11,959,384	$	—	$	39,055,236
		31-Dec-12
			Quoted Prices in Active Markets for Identical Assets (Level 1)
					Significant Other Observable Inputs (Level 2)
							Significant Unobservable Inputs
							(Level 3)
									Total
	Assets:
	Repurchase agreement (cash equivalents)	$	12,004,575	$	—	$	—	$	12,004,575
	Total assets measured at fair value	$	12,004,575	$	—	$	—	$	12,004,575

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, All Other Investments [Abstract]	'
Available-for-sale investments	'
					Gross Unrealized Gains		Gross Unrealized Losses
			Amortized Cost
										Fair Value
	Asset-backed securities	$	500,113	$	—	$	(86	)	$	500,027
	Corporate notes and bonds		11,437,541		22,825		(1,009	)		11,459,357
	Total	$	11,937,654	$	22,825	$	(1,095	)	$	11,959,384
	The following table summarizes the maturities of the Company’s available-for-sale securities at December 31, 2013:
		Amortized		Fair Value
		Cost
	Due in less than 1 year	$	4,999,251	$	5,001,969
	Due in 1-2 years		6,938,403		6,957,415
	Total	$	11,937,654	$	11,959,384

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	PROPERTY AND EQUIPMENT
			12/31/13			12/31/12
	Computer equipment	$	566,471		$	89,109
	Laboratory and scientific equipment		791,295			323,151
	Furniture and fixtures		36,988			36,988
	Leasehold improvements		278,791			39,741
	Total property and equipment	$	1,673,545		$	488,989
	Accumulated depreciation		(626,771	)		(341,178	)
	Net property and equipment	$	1,046,774		$	147,811

Intellectual_Property_Tables

Intellectual Property (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Finite-Lived Intangible Assets	'
	INTELLECTUAL PROPERTY
				12/31/13				12/31/12
	OptiChem Technologies		$	192,954			$	192,954
	Patents			210,125				211,833
	Subtotal		$	403,079			$	404,787
	Accumulated amortization			(162,411	)			(85,507	)
	Net intellectual property		$	240,668			$	319,280
Future Amortization Expense	'
	Years Ending December 31,
		2014			$	63,313
		2015				8,082
		2016				8,082
		2017				8,082
		Thereafter				153,109
		Total future amortization			$	240,668

Deferred_Revenue_and_Income_Ta

Deferred Revenue and Income (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Deferred Revenue and Income Summary	'
	Deferred Revenue and Income
			12/31/13		12/31/12
	Schott Royalties (see Note 7)	$	68,555	$	72,757
	NanoString (see Note 7)		—		5,276
	Fisher Agreement		13,333		—
	Total deferred revenue and income	$	81,888	$	78,034
	Arizona Commerce Authority Grant (see Note 7)	$	750,000		—
	Fisher Agreement		26,667		—
	Total Long-term deferred income	$	776,667	$	0

Employee_Stock_Based_Compensat1

Employee Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Option Plans	'
					Weighted
					Average
		Number of	Exercise Price		Exercise Price
		Shares	Per Share		Per Share
	Options Outstanding July 31, 2012	3,180,000	$0.73-4.50	$	1.56
	Granted	1,433,000	$2.98-3.95	$	3.65
	Cancelled	250,000	$2.25-4.50	$	3.34
	Exercised	—	—		—
	Expired	2,500	$2.36-3.20	$	3.02
	Options Outstanding December 31, 2012	4,360,500	$0.73-3.95	$	2.14
	Granted	1,308,086	$3.45-13.30	$	7.56
	Cancelled	58,000	$2.69-9.83	$	6.47
	Exercised	328,000	$1.04-3.69	$	2.54
	Expired	122,500	$0.73-3.20	$	1.78
	Options Outstanding December 31, 2013	5,160,086	$1.04-13.30	$	3.45
Outstandinig Stock Options	'
			Outstanding				Exercisable
	Range of Exercise Price	Number of Shares	Weighted Average Remaining Contractual Life		Weighted Average Exercise Price	Number of Shares	Weighted Average Remaining Contractual Life		Weighted Average Exercise Price
	$0 to $3.50	2,605,000	8.17	$	1.31	775,000	7.73	$	1.4
	$3.51 to $7.00	2,053,691	8.69		4.45	244,120	7.05		5.01
	$7.01 to $10.50	394,500	9.66		9.71	—	—		—
	$10.51 to $13.50	106,895	9.85		13.3	1,936	9.85		13.3
	Total	5,160,086	8.53	$	3.45	1,021,056	7.57		2.29

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income tax Provision	'
				12/31/13			12/31/12		7/31/12		7/31/11
	Current		$	—		$	—	$	—	$	—
	Deferred			—			—		—		—
	Total		$	—		$	—	$	—	$	—
Deferred Income Taxes	'
			12/31/13			12/31/12
	Deferred tax assets:
	Intangible assets, definite-lived	$	478,000		$	452,000
	Property & equipment		21,000			—
	Deferred revenue		26,000			30,000
	Charitable contribution		11,000			6,000
	Stock options		516,000			172,000
	Officer’s compensation		—			270,000
	General business credit		637,000			144,000
	Net operating loss carryforward		8,595,000			4,083,000
	Valuation allowance		(10,284,000	)		(5,156,000	)
	Deferred tax assets	$	—		$	1,000
	Deferred tax liabilities:
	Property & equipment	$	—		$	(1,000	)
	Total deferred tax liabilities	$	—		$	(1,000	)
	Total net deferred taxes	$	—		$	—
Tax Compensation Expense	'
	Fiscal year ended,		12/31/13			12/31/12		7/31/12		7/31/11
	U.S. Federal statutory income tax rate		(34.00	)%		(34.00	)%	(34.00	)%	(34.00	)%
	State taxes, net of federal tax benefit		(3.80	)		(2.70	)	(3.00	)	(3.00	)
	Change in state rate		0			(0.90	)	—		—
	Non-deductible equity and other compensation		6.5			4.2		5.19		0.1
	Limitation on net operating losses due to S382		1			32.5		—		—
	Removal of Colorado net operating losses		0			10.8		—		—
	Prior period net operating loss correction		—			—		(1.70	)	—
	Credit for increased research activities		(3.20	)		—		—		—
	Change in valuation allowance		33.5			(9.90	)	33.51		36.9
			0	%		0	%	0	%	0	%

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Lease Obligations	'
			2014		2015		2016		2017		2018
	Operating Lease Obligations	$	141,664	$	141,664	$	1,164	$	—	$	—

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies Details Narrative	'	'
Uninsured cash balances	$30,105,171	$12,004,575

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details Narrative 1)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary Of Significant Accounting Policies Details Narrative 1	'	'
Antidilutive common stock instruments outstanding	5,731,246	18,431,930

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Total	'	'
Assets:	'	'
Money market funds (cash equivalents)	$27,095,852	'
Corporate notes and bonds	11,459,357	'
Asset-backed securities	500,027	'
Total assets measured at fair value	39,055,236	'
Repurchase agreement (cash equivalents)	'	12,004,575
Total assets measured at fair value	'	12,004,575
Significant Unobservable Inputs (Level 3)	'	'
Assets:	'	'
Money market funds (cash equivalents)	'	'
Corporate notes and bonds	'	'
Asset-backed securities	'	'
Total assets measured at fair value	'	'
Repurchase agreement (cash equivalents)	'	'
Total assets measured at fair value	'	'
Significant Other Observable Inputs (Level 2)	'	'
Assets:	'	'
Money market funds (cash equivalents)	'	'
Corporate notes and bonds	11,459,357	'
Asset-backed securities	500,027	'
Total assets measured at fair value	11,959,384	'
Repurchase agreement (cash equivalents)	'	'
Total assets measured at fair value	'	'
Quoted Prices in Active Markets for Identical Assets (Level 1)	'	'
Assets:	'	'
Money market funds (cash equivalents)	27,095,852	'
Corporate notes and bonds	'	'
Asset-backed securities	'	'
Total assets measured at fair value	27,095,852	'
Repurchase agreement (cash equivalents)	'	12,004,575
Total assets measured at fair value	'	$12,004,575

Investments_Details_Narrative

Investments (Details Narrative) (USD $)	Dec. 31, 2013
Fair Value	'
Asset-backed securities	$500,027
Corporate notes and bonds	11,459,357
Total	11,959,384
Gross Unrealized Losses	'
Asset-backed securities	-86
Corporate notes and bonds	-1,009
Total	-1,095
Gross Unrealized Gains	'
Asset-backed securities	0
Corporate notes and bonds	22,825
Total	22,825
Amortized Cost	'
Asset-backed securities	500,113
Corporate notes and bonds	11,437,541
Total	$11,937,654

Investments_Details_Narrative_

Investments (Details Narrative 1) (USD $)	Dec. 31, 2013
Fair Value	'
Due in less than 1 year	$5,001,969
Due in 1 to 2 years	6,957,415
Total	11,959,384
Amortized Cost	'
Due in less than 1 year	4,999,251
Due in 1 to 2 years	6,938,403
Total	$11,937,654

Property_and_Equipment_Propert

Property and Equipment - Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property And Equipment - Property And Equipment Details	'	'
Computer equipment	$566,471	$89,109
Laboratory and scientific equipment	791,295	323,151
Furniture and fixtures	36,988	36,988
Leasehold improvements	278,791	39,741
Total property and equipment	1,673,545	488,989
Accumulated depreciation	-626,771	-341,178
Net property and equipment	$1,046,774	$147,811

Property_and_Equipment_Details

Property and Equipment (Details Narrative) (USD $)	5 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Property And Equipment Details Narrative	'	'	'	'	'
Depreciation expense	$4,644	$515	$285,592	$2,097	$2,396

Intellectual_Property_FiniteLi

Intellectual Property - Finite-Lived Intangible Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Intellectual Property - Finite-Lived Intangible Assets Details	'	'
OptiChem Technologies	$192,954	$192,954
Patents	210,125	211,833
Total	403,079	404,787
Accumulated amortization	-162,411	-85,507
Net intellectual property	$240,668	$319,280

Intellectual_Property_Future_A

Intellectual Property - Future Amortization Expense (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Intellectual Property - Future Amortization Expense Details	'	'
Year Ending December 31, 2014	$63,313	'
Year Ending December 31, 2015	8,082	'
Year Ending December 31, 2016	8,082	'
Year Ending December 31, 2017	8,082	'
Thereafter	153,109	'
Total future amortization	$240,668	$319,280

Intellectual_Property_Details_

Intellectual Property (Details Narrative) (USD $)	5 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Intellectual Property Details Narrative	'	'	'	'	'
Amortization expense	$38,023	$64,087	$76,903	$203,460	$253,499
Reduction of amortized book value	$333,487	$0	$11,352	$1,996,583	$0

License_Agreements_and_Grants_

License Agreements and Grants (Details Narrative) (USD $)	5 Months Ended		12 Months Ended			39 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Nov. 24, 2014
License Agreements And Grants Details Narrative	'	'	'	'	'	'
SCHOTT one-time license fee	'	'	'	'	'	$50,000
Non-refundable prepaid royalties	'	'	'	$100,000	'	$100,000
Royalties percent of net product sales	'	'	'	'	'	5.00%

License_Agreements_and_Grants_1

License Agreements and Grants (Details Narrative 1) (USD $)	Jul. 09, 2010
License Agreements And Grants Details Narrative 1	'
OptiChem non-exclusive license with Nanosphere	$150,000
Technology transfer fee	15,000
OptiChem non-exclusive license with Nanosphere first year anniversary	350,000
OptiChem non-exclusive license with Nanosphere second year anniversary	600,000
OptiChem non-exclusive license with Nanosphere third year anniversary	$750,000

License_Agreements_and_Grants_2

License Agreements and Grants (Details Narrative 2) (USD $)	1 Months Ended	12 Months Ended
	31-May-12	Dec. 31, 2013	Dec. 31, 2012
License Agreements And Grants Details Narrative 2	'	'	'
Research and development project	$650,000	'	'
Offset to research and development project	'	$142,591	$15,696

License_Agreements_and_Grants_3

License Agreements and Grants (Details Narrative 3) (USD $)	Dec. 31, 2013	Aug. 22, 2012	Aug. 20, 2012
License Agreements And Grants Details Narrative 3	'	'	'
Grant agreement	'	$1,000,000	'
Capital investment	'	4,520,000	'
Qualified job wages	'	63,000	70,000
Qualified job benefits	'	65.00%	'
Deferred revenue from grant agreement	$750,000	'	'

Deferred_Revenue_and_Income_De

Deferred Revenue and Income (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Revenue And Income Details	'	'
Schott Royalties	$68,555	$72,757
NanoString	'	5,276
Fisher Agreement	13,333	'
Total deferred revenue and income	81,888	78,034
Arizona Commerce Authority Grant	750,000	'
Fisher Agreement	26,667	'
Total Long-term deferred income	$776,667	$0

Deferred_Revenue_and_Income_De1

Deferred Revenue and Income (Details Narrative) (USD $)	5 Months Ended		12 Months Ended			39 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Nov. 24, 2014
Deferred Revenue And Income Details Narrative	'	'	'	'	'	'
Deferred revenue recognization	$7,311	$4,521	$9,478	$24,452	$10,428	'
Prepaid royalty fees	'	'	'	100,000	'	100,000
Additional prepaid royalty fees	$7,311	$0	$4,202	$19,931	$0	'

Stock_Purchase_Details_Narrati

Stock Purchase (Details Narrative) (USD $)	Jul. 08, 2013	Mar. 06, 2013	Apr. 20, 2012
Securities Purchase Agreement Dated April 20, 2012	'	'	'
Shares of common stock	'	'	14,000,000
Price per share	$8.04	'	$1.03
Warrants to purchase common stock	'	'	7,000,000
Price per warrant	'	'	1.03
Exercised warrant per purchase agreement	'	7,000,000	'
Price per warrant	'	1.03	'
Additional warrant to purchase common stock	'	'	7,000,000
Price per warrant	'	'	2
Additional exercised warrant per purchase agreement	'	6,428,840	'
Price per warrant	'	2	'
Value of common stock	'	'	$8,523,982
Value of warrants	'	'	$5,896,018

Rights_Offering_Details_Narrat

Rights Offering (Details Narrative) (USD $)	Aug. 08, 2013	Jul. 08, 2013	Mar. 06, 2013	Apr. 20, 2012
Rights Offering Details Narrative	'	'	'	'
Non-transferable subscription rights for each share of common stock owned on the record date	'	0.064038	'	'
Subscription right to purchase common stock price per share	'	$8.04	'	$1.03
Standby purchase agreement issuance of unsubscribed shares to related party	2,487,562	'	'	'
Gross proceeds from standby purchase agreement	$20,000,000	'	'	'
Costs associated with rights offering	$88,785	'	'	'

Employee_Stock_Based_Compensat2

Employee Stock Based Compensation - Stock Option Plans (Details) (USD $)	5 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Jul. 31, 2012
Number of Shares	'	'	'
Options Outstanding, beginning balance	3,180,000	4,360,500	750,000
Shares Granted	1,433,000	1,308,086	2,510,000
Shares Cancelled	250,000	58,000	80,000
Shares Exercised	'	328,000	'
Shares Expired	2,500	122,500	'
Options Outstanding, ending balance	4,360,500	5,160,086	3,180,000
Exercise Price Per Share	'	'	'
Options Outstanding, Lower Range, beginning balance	$0.73	$0.73	$0.73
Options Outstanding, Upper Range, beginning balance	$4.50	$3.95	$4.50
Shares Granted, Lower range	$2.98	$3.45	$1.04
Shares Granted, Upper range	$3.95	$13.30	$3.13
Shares Cancelled, Lower range	$2.25	$2.69	$2.50
Shares Cancelled, Upper range	$4.50	$9.83	$2.69
Shares Exercised, Lower range	'	$1.04	'
Shares Exercised, Upper range	'	$3.69	'
Shares Expired, Lower range	$2.36	$0.73	'
Shares Expired, Upper range	$3.20	$3.20	'
Options Outstanding, Lower Range, ending balance	$0.73	$1.04	$0.73
Options Outstanding, Upper Range, ending balance	$3.95	$13.30	$4.50
Weighted Average Exercise Price	'	'	'
Options Outstanding, beginning balance	$1.56	$2.14	$2.91
Shares Granted	$3.65	$7.56	$1.17
Shares Cancelled	$3.34	$6.47	$2.67
Shares Exercised	'	$2.54	'
Shares Expired	$3.02	$1.78	'
Options Outstanding, ending balance	$2.14	$3.45	$1.56

Employee_Stock_Based_Compensat3

Employee Stock Based Compensation - Stock Option Exercise Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
	Decimal
Outstanding, Number of Shares	5,160,086
Outstanding, Weighted Average Remaining Contractual Life	8.53
Outstanding, Weighted Average Exercise Price	$3.45
Exercisable, Number of Shares	1,021,056
Exercisable, Weighted Average Remaining Contractual Life	7.57
Exercisable, Weighted Average Exercise Price	$2.29
$0 to $3.50	'
Range of Exercise Price, Lower	$0
Range of Exercise Price, Upper	$3.50
Outstanding, Number of Shares	2,605,000
Outstanding, Weighted Average Remaining Contractual Life	8.17
Outstanding, Weighted Average Exercise Price	$1.31
Exercisable, Number of Shares	775,000
Exercisable, Weighted Average Remaining Contractual Life	7.73
Exercisable, Weighted Average Exercise Price	$1.40
$3.51 to $7.00	'
Range of Exercise Price, Lower	$3.51
Range of Exercise Price, Upper	$7
Outstanding, Number of Shares	2,053,691
Outstanding, Weighted Average Remaining Contractual Life	8.69
Outstanding, Weighted Average Exercise Price	$4.45
Exercisable, Number of Shares	244,120
Exercisable, Weighted Average Remaining Contractual Life	7.05
Exercisable, Weighted Average Exercise Price	$5.01
$7.01 to $10.50	'
Range of Exercise Price, Lower	$7.01
Range of Exercise Price, Upper	$10.50
Outstanding, Number of Shares	394,500
Outstanding, Weighted Average Remaining Contractual Life	9.66
Outstanding, Weighted Average Exercise Price	$9.71
Exercisable, Number of Shares	'
Exercisable, Weighted Average Exercise Price	'
$10.51 to $13.50	'
Range of Exercise Price, Lower	$10.51
Range of Exercise Price, Upper	$13.50
Outstanding, Number of Shares	106,895
Outstanding, Weighted Average Remaining Contractual Life	9.85
Outstanding, Weighted Average Exercise Price	$13.30
Exercisable, Number of Shares	1,936
Exercisable, Weighted Average Remaining Contractual Life	9.85
Exercisable, Weighted Average Exercise Price	$13.30

Employee_Stock_Based_Compensat4

Employee Stock Based Compensation - Outstanding Stock Options (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013
Qualified Plan	'
Options exercised	322,500
Options outstanding	235,000
Options available	'
Non-Qualified Plan	'
Options exercised	$245,000
Options outstanding	10,000
Options available	'
Omnibus Stock Option and Equity Incentive Plan	'
Shares authorized	5,500,000
Options exercised	268,000
Options outstanding	4,915,086
Options available	316,914

Employee_Stock_Based_Compensat5

Employee Stock Based Compensation - Outstanding Stock Options (Details Narrative 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Based Compensation - Outstanding Stock Options Details Narrative 1	'	'
Options outstanding and exercisable	1,021,056	1,360,500
Weighted average exercise price	$2.29	$1.92

Employee_Stock_Based_Compensat6

Employee Stock Based Compensation - Employee Based Option Plans (Details Narrative) (USD $)	5 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011
Employee Stock Based Compensation - Employee Based Option Plans Details Narrative	'	'	'	'	'
Recognized stock based compensation costs	$532,705	$272,529	$3,828,478	$781,998	$90,021
Unrecognized share-based compensation costs	$3,421,901	'	$6,339,510	'	'

Employee_Stock_Based_Compensat7

Employee Stock Based Compensation - Employee Based Option Plans (Details Narrative 1)	12 Months Ended
	Dec. 31, 2013
	Y
Weighted-average assumptions used for valuation under the Black-Scholes model	'
Risk-free interest rate, high	2.19%
Risk-free interest rate, low	0.79%
Dividend yield	0.00%
Volatility factor, high	100.00%
Volatility factor, low	91.00%
Expected option life in years, high	6.5
Expected option life in years, low	5.27
Weighted-average contractual life of stock options outstanding	'8 years 6 months

Income_Taxes_IncomeTax_Provisi

Income Taxes - IncomeTax Provision (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2012	Jul. 31, 2011
Income Taxes - Incometax Provision Details	'	'	'	'
Current	'	'	'	'
Deferred	'	'	'	'
Total	'	'	'	'

Income_Taxes_Deferred_Income_T

Income Taxes - Deferred Income Taxes (Details) (USD $) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Intangible assets, definite lived	$478,000	$452,000
Property & equipment	21,000	'
Deferred revenue	26,000	30,000
Charitable contributions	11,000	6,000
Stock options	516,000	172,000
Officer's compensation	'	270,000
General business credits	637,000	144,000
Net operating loss carry-forward	8,595,000	4,083,000
Valuation allowance	-10,284,000	-5,156,000
Deferred tax asset	'	1,000
Deferred tax liabilities:	'	'
Property & equipment	'	-1,000
Total deferred tax liabilities	'	-1,000
Total net defered taxes	'	'

Income_Taxes_Tax_computation_e

Income Taxes - Tax computation expense (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2012	Jul. 31, 2011
Income Taxes - Tax Computation Expense Details	'	'	'	'
U.S. Federal statutory income tax rate	-34.00%	-34.00%	-34.00%	-34.00%
State taxes, net of federal tax benefit	-3.80%	-2.70%	-3.00%	-3.00%
Change in state rate	0.00%	-0.90%	'	'
Non-deductible equity and other compensation	6.50%	4.20%	5.19%	0.10%
Limitation on net operating losses due to S382	1.00%	32.50%	'	'
Removal of Colorado net operating losses	0.00%	10.80%	'	'
Prior period net operating loss correction	'	'	-1.70%	'
Credit for increased research activities	-3.20%	'	'	'
Change in valuation allowance	33.50%	-9.90%	33.51%	36.90%
Total	0.00%	0.00%	0.00%	0.00%

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Income Taxes Details Narrative	'	'
Deferred tax asset valuation allowance	$10,284,000	$5,156,000

Income_Taxes_Details_Narrative1

Income Taxes (Details Narrative 1) (USD $) (USD $)	Dec. 31, 2013
Income Taxes Details Narrative 1 Usd	'
Company generated tax net operating loss	$28,000,000
Loss of net operating loss benefit	420,000
Tax net operating loss	$24,000,000
Loss carryforward expiration date	'available to offset future taxable income which will begin to expire in 2023.

Commitments_Lease_Obligations_

Commitments - Lease Obligations (Details) (USD $)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments - Lease Obligations Details	'	'	'	'	'	'
Operating Lease Obligations	'	'	$1,164	$141,664	$141,664	$167,863

Commitments_Employment_Agreeme

Commitments - Employment Agreement (Details Narrative) (USD $)	12 Months Ended		61 Months Ended
	Dec. 31, 2013	Jul. 31, 2012	Dec. 31, 2012	Jul. 01, 2013	Jun. 26, 2012
Employee Agreement	'	'	'	'	'
Base salary	'	'	$165,000	'	'
Deferred compensation	'	'	75,000	'	'
Amended agreement payment	'	'	'	'	650,000
Closing investment payment	'	'	'	700,000	'
Consulting Agreement	'	'	'	'	'
Monthly payment	'	24,000	'	'	'
Consulting fee	$96,000	'	'	'	'

Commitments_Operating_Lease_De

Commitments - Operating Lease (Details Narrative) (USD $)	5 Months Ended		12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Jul. 31, 2012	Jul. 31, 2011	Aug. 22, 2012	Aug. 20, 2012
Commitments - Operating Lease Details Narrative	'	'	'	'	'	'	'
Rent expense	$39,867	$35,470	$10,844	$73,965	$68,330	'	'
Pima County Lease Agreement	'	'	'	'	'	'	'
Initial term rent per year	'	'	'	'	'	'	139,600
Initial term price per square foot	'	'	'	'	'	'	9.25
Renewal term rent per year	'	'	'	'	'	'	298,900
Renewal term rent per square foot	'	'	'	'	'	'	19.8
Qualified job wages	'	'	'	'	'	$63,000	$70,000

Commitments_Operating_Lease_De1

Commitments - Operating Lease (Details Narrative 1) (USD $)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments - Operating Lease Details Narrative 1	'	'	'	'	'	'
Rent expense for relocation of headquarters	'	'	$1,164	$141,664	$141,664	$167,863

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	Jan. 08, 2014
Certificate of Qualification	'
Research and development expense	$703,377
Eligible refund	$527,495